Catalyst Wire Dossier Catalyst Wire Dossier

GWP42003-P (cannabidiol oral solution)

cannabidiol · Jazz Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GWP42003-P (cannabidiol oral solution), covering 2025-10-31 to 2025-10-31. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures [Phase 3]

See pricing